Cite
HARVARD Citation
Behringer, K. et al. (2015). Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 385 (9976), pp. 1418-1427. [Online].